Search clinical trials for: LY3090106

Total 135 results

Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
Eli Lilly and Company

Active, not recruiting

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Uveitis

France, Spain, Germany, United Kingdom, Italy
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
Eli Lilly and Company
AstraZeneca

Completed

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Hepatocellular Carcinoma | Gastric Cancer | Non-Small Cell Lung Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Spain, Korea, Republic of, Taiwan, Germany, Italy, France, Israel
Eli Lilly and Company

Completed

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Rectal Cancer | Colon Cancer

United States, Canada
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Hepatocellular Carcinoma

United States
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

China, Argentina, Brazil
Eli Lilly and Company
Incyte Corporation

Completed

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (BREEZE-AD4)

Atopic Dermatitis

Belgium, Netherlands, Japan, Spain, Switzerland, United Kingdom, Germany, France, Austria, Russian Federation, Poland, Italy, Brazil, Finland
Eli Lilly and Company

Withdrawn

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer
Eli Lilly and Company

Completed

A Study of Baricitinib and Omeprazole in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

Urothelial Carcinoma

Spain, United States, Poland, Romania, Taiwan, Ukraine, Netherlands, Mexico, Japan, France, Germany, Belgium, Greece, Russian Federation, Turkey, Canada, Israel, Italy, United Kingdom, Denmark, Korea, Republic of, Australia, Hungary
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Gastric Cancer | Gastroesophageal Junction Region (GEJ) Cancer

Japan
Eli Lilly and Company

Completed

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Malignant Solid Tumor

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

Breast Cancer | Metastatic Breast Cancer

Japan
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China, Malaysia, Thailand, Philippines
Eli Lilly and Company

Completed

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Breast Cancer

United States, Canada
Eli Lilly and Company

Completed

A Study of Baricitinib and Simvastatin in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Breast Cancer

United States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Adenocarcinoma | Gastric Cancer

United States, Canada, Brazil, Czechia, Egypt, Korea, Republic of, Lebanon, Poland, Russian Federation, Spain, Romania, United Kingdom, Australia, Croatia, Italy, Philippines, Thailand, Argentina, Bosnia and Herzegovina, Chile, ... and more
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, United Kingdom
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Malignant Solid Tumor

United States
Eli Lilly and Company

No longer available

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Japan
Eli Lilly and Company

Completed

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Stomach Neoplasms

Japan
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Italy, United States, Spain, Ukraine, Germany, Greece, Czechia, Turkey, Belgium, Sweden, Canada
Eli Lilly and Company

Completed

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Active, not recruiting

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

Pancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)

France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
Eli Lilly and Company
AstraZeneca

Completed

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Non-small Cell Lung Cancer

Spain, United States, Korea, Republic of, Taiwan, France
Eli Lilly and Company

Terminated

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Synovial Sarcoma

United States, Spain, France, United Kingdom, Australia, Germany, Japan, Italy, Belgium, Netherlands
University of Southern California
National Cancer Institute (NCI)

Terminated

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Eli Lilly and Company

Completed

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Adenocarcinoma

Japan
Eli Lilly and Company

Completed

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Carcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal Pelvis

United States, Canada
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Germany, Italy, Spain, United States, Hungary, Russian Federation, Poland, Belgium, Netherlands, France, Czechia, Mexico, Argentina, Canada, Denmark, Finland, Israel, Japan, Puerto Rico, United Kingdom
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)

Gastric Cancer

United States, Australia, Belgium, Korea, Republic of, Russian Federation, Germany, Poland, Spain, Argentina, Austria, Brazil, Bulgaria, Chile, Estonia, France, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Sing... and more
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
Eli Lilly and Company

Completed

A Study of Baricitinib and Ciclosporin in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company
Incyte Corporation

Completed

A Study of LY3009104 in Healthy Participants

Healthy Participants

United States
Athenex, Inc.

Active, not recruiting

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Gastric Cancer | Esophageal Cancer | Gastro-esophageal Cancer

Taiwan, United States
Eli Lilly and Company

Completed

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, France, Belgium
Eli Lilly and Company

Completed

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, Taiwan, Japan
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen

Metrorrhagia
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Metastatic Cancer | Advanced Cancer | Biliary Tract Cancer

United States, Belgium, Spain, Australia, Czechia, Denmark, Korea, Republic of, Taiwan, Germany, Turkey, France, United Kingdom, Austria, Russian Federation, Mexico, Hungary, Argentina, Sweden
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Gastric Adenocarcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
Eli Lilly and Company

Completed

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Carcinoma, Hepatocellular

Taiwan
Eli Lilly and Company

Completed

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Stomach Cancer | Esophageal Cancer

United States
Eli Lilly and Company

Completed

A Study of LY2801653 in Advanced Cancer

Cancer

United States

Search clinical trials for: LY3090106

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations